Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 2/2013

01-04-2013

Current concepts in the imaging of uterine sarcoma

Authors: Sree Harsha Tirumani, Vijayanadh Ojili, Alampady Krishna Prasad Shanbhogue, Najla Fasih, John G. Ryan, Caroline Reinhold

Published in: Abdominal Radiology | Issue 2/2013

Login to get access

Abstract

Recent advances in genetics and pathology have improved our understanding of diagnosis and staging of uterine sarcomas. The major types of uterine sarcomas include leiomyosarcoma, low-grade endometrial stromal sarcoma, undifferentiated endometrial sarcoma, adenosarcoma and carcinosarcoma. The distinctive biological behavior and poor overall survival of uterine sarcoma create challenges in the management of these tumors. We herein present a comprehensive review of taxonomy, epidemiology, pathology, imaging findings and natural history of a wide spectrum of uterine sarcomas.
Literature
1.
Major FJ, Blessing JA, Silverberg SG, et al. (1993) Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71(Suppl 4):1702–1709PubMedCrossRef
2.
Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A (2008) Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol 111:74–81PubMedCrossRef
3.
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 260:277–300CrossRef
4.
Abeler VM, Royne O, Thoresen S, et al. (2009) Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364PubMedCrossRef
5.
6.
Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press
7.
8.
Wu TI, Yen TC, Lai CH (2011) Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 25:681–689PubMedCrossRef
9.
Royal College of Pathologists (2011) Standards and datasets for reporting cancers. Dataset for histological reporting of uterine sarcomas. London: Royal College of Pathologists
10.
Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I (2009) Clinical management of uterine sarcomas. Lancet Oncol 10:1188–1198PubMedCrossRef
11.
Schwartz LB, Zawin M, Carcangui MA, Lange R, McCarthy S (1998) Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril 70:580–587PubMedCrossRef
12.
Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H (2004) Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 20:998–1007PubMedCrossRef
13.
Cornfield D, Israel G, Martel M, et al. (2010) MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol 74:241–249CrossRef
14.
Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112:820–830PubMedCrossRef
15.
Pelmus M, Penault-Llorca F, Guillou L, et al. (2009) Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer 19:385–390PubMedCrossRef
16.
Renzulli P, Weimann R, Barras JP, Carrel TP, Candinas D (2009) Low-grade endometrial stromal sarcoma with inferior vena cava tumor thrombus and intracardiac extension: radical resection may improve recurrence free survival. Surg Oncol 18:57–64PubMedCrossRef
17.
Nucci MR, Harburger D, Koontz J, Dal Cin P, Sklar J (2007) Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol 31:65–70PubMedCrossRef
18.
Gandolfo N, Gandolfo NG, Serafini G, Martinoli C (2000) Endometrial stromal sarcoma of the uterus: MR and US findings. Eur Radiol 10:776–779PubMedCrossRef
19.
Koyama T, Togashi K, Konishi I, et al. (1999) MR imaging of endometrial stromal sarcoma: correlation with pathologic findings. AJR Am J Roentgenol 173:767–772PubMedCrossRef
20.
Fujii S, Kaneda S, Tsukamoto K, et al. (2010) Diffusion-weighted imaging of uterine endometrial stromal sarcoma: a report of 2 cases. J Comput Assist Tomogr 34:377–379PubMedCrossRef
21.
Tamai K, Koyama T, Saga T, et al. (2008) The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 18:723–730PubMedCrossRef
22.
Furukawa R, Akahane M, Yamada H, et al. (2010) Endometrial stromal sarcoma located in the myometrium with a low-intensity rim on T2-weighted images: report of three cases and literature review. J Magn Reson Imaging 31:975–979PubMedCrossRef
23.
Thomas MB, Keeney GL, Podratz KC, Dowdy SC (2009) Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer 19:253–256PubMedCrossRef
24.
Shah JP, Bryant CS, Kumar S, et al. (2008) Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 112:1102–1108PubMedCrossRef
25.
Garg G, Shah JP, Toy EP, et al. (2010) Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol 118:8–13PubMedCrossRef
26.
Silva EG, Deavers MT, Malpica A (2007) Undifferentiated carcinoma of the endometrium: a review. Pathology 39:134–138PubMedCrossRef
27.
Rha SE, Byun JY, Jung SE, et al. (2003) CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol 181:1369–1374PubMedCrossRef
28.
Chourmouzi D, Boulogianni G, Zarampoukas T, Drevelengas A (2003) Sonography and MRI of tamoxifen-associated Müllerian adenosarcoma of the uterus. AJR Am J Roentgenol 181:1673–1675PubMedCrossRef
29.
Clement PB, Scully RE (1990) Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 21:363–381PubMedCrossRef
30.
Szklaruk J, Tamm EP, Choi H, Varavithya V (2003) MR imaging of common and uncommon large pelvic masses. Radiographics 23:403–424PubMedCrossRef
31.
Farhat MH, Hobeika EM, Moumneh G, Nassar AH (2007) Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report. J Med Case Rep 1:103PubMedCrossRef
32.
Kim SA, Jung JS, Ju SJ, Kim YT, Kim KR (2011) Mullerian adenosarcoma with sarcomatous overgrowth in the pelvic cavity extending into the inferior vena cava and the right atrium. Pathol Int 61:445–448PubMedCrossRef
33.
Kernochan LE, Garcia RL (2009) Carcinoasarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 7:550–557PubMed
34.
Kanthan R, Senger JL (2011) Uterine carcinosarcomas (malignant mixed Müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. doi:10.​1155/​2011/​470795
35.
Teo SY, Babagbemi KT, Peters HE, Mortele KJ (2008) Primary malignant mixed Müllerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. AJR Am J Roentgenol 191:278–283PubMedCrossRef
36.
Bharwani N, Newland A, Tunariu N, et al. (2010) MRI appearances of uterine malignant mixed Müllerian tumors. AJR Am J Roentgenol 195:1268–1275PubMedCrossRef
37.
Genever AV, Abdi S (2011) Can MRI predict the diagnosis of endometrial carcinosarcoma? Clin Radiol 66:621–624PubMedCrossRef
38.
Ohguri T, Aoki T, Watanabe H, et al. (2002) MRI findings including gadolinium-enhanced dynamic studies of malignant, mixed mesodermal tumors of the uterus: differentiation from endometrial carcinomas. Eur Radiol 12:2737–2742PubMed
39.
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31:1653–1661PubMedCrossRef
40.
Huang GS, Chiu LG, Gebb JS, Gunter MJ, et al. (2007) Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 107:513–517PubMedCrossRef
41.
Levy A, Medjhoul A, Caramella C, et al. (2011) Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review. J Magn Reson Imaging 33:1020–1027PubMedCrossRef
42.
Fujii S, Matsusue E, Kigawa J, et al. (2008) Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol 18:384–389PubMedCrossRef
43.
Namimoto T, Yamashita Y, Awai K, et al. (2009) Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 19:2756–2764CrossRef
44.
Kato H, Kanematsu M, Furui T, et al. (2008) Carcinosarcoma of the uterus: radiologic–pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging. Magn Reson Imaging 26:1446–1450PubMedCrossRef
45.
Tsujikawa T, Yoshida Y, Mori T, et al. (2008) Uterine tumors: pathophysiologic imaging with 16α-[18F] fluoro-17β-estradiol and 18F-fluorodeoxyglucose PET—initial experience. Radiology 248:599–605PubMedCrossRef
46.
Nagamatsu A, Umesaki N, Li L, Tanaka T (2010) Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep 23:1069–1076PubMed
47.
Kao YH, Saad U, Tan AE, Magsombol BM, Padhy AK (2011) Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta Radiol 52:463–466PubMedCrossRef
48.
FIGO Committee on Gynecologic Oncology (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104:179CrossRef
49.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
50.
Seddon BM, Davda R (2011) Uterine sarcomas—recent progress and future challenges. Eur J Radiol 78:30–40PubMedCrossRef
51.
Gadducci A, Cosio S, Romanini A, Genazzani A (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129–142PubMedCrossRef
Metadata
Title
Current concepts in the imaging of uterine sarcoma
Authors
Sree Harsha Tirumani
Vijayanadh Ojili
Alampady Krishna Prasad Shanbhogue
Najla Fasih
John G. Ryan
Caroline Reinhold
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9919-x

Other articles of this Issue 2/2013

Abdominal Radiology 2/2013 Go to the issue

Report

Renal vein leiomyosarcoma: imaging and clinical features of a renal cell carcinoma mimic

Report

Lower gastrointestinal bleeding due to primary ilioenteric fistula

OriginalPaper

Dose reduction methods for CT colonography

OriginalPaper

Epithelioid angiomyolipoma of the liver: CT and MRI features

OriginalPaper

Routine use of precontrast and delayed acquisitions in abdominal CT: time for change

OriginalPaper

Percutaneous, computed tomography-guided drainage of deep pelvic abscesses via a transgluteal approach: a report on 30 cases and a review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits